In conclusion, the first published phase II study demonstrated that the neoadjuvant regimen containing PLD plus docetaxel and trastuzumab showed good antitumor activity for patients with stage II or III HER2-positive BC, with a relatively high tpCR and bpCR rate. Here, ERBB2 is linked to breast cancer.